Effects of antihypertensive treatment on endothelial function in postmenopausal hypertensive women. A significant role for aldosterone inhibition

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 12, Issue 4, 2011, Pages 446-455

  Rossi, Rosario ^a   Nuzzo, Annachiara ^a   Iaccarino, Daniele ^a   Lattanzi, Antonella ^a   Origliani, Giorgia ^a   Monopoli, Daniel Enrique ^a   Modena, Maria Grazia ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Aldosterone; antihypertensive therapy; endothelium; hypertension; vasodilation

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANRENOATE POTASSIUM; CANRENONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTERY BLOOD FLOW; ARTERY DILATATION; ARTICLE; BLOOD PRESSURE REGULATION; BRACHIAL ARTERY; COHORT ANALYSIS; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; GYNECOMASTIA; HIRSUTISM; HORMONE INHIBITION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ULTRASOUND;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DEMOGRAPHY; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HEMORHEOLOGY; HUMANS; HYPERTENSION; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; REGRESSION ANALYSIS; VASODILATION;

EID: 83455219445     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320311415134     Document Type: Article

References (36)

1. Lüscher TF, Vanhoutte PM The endothelium: modulator of cardiovascular function. Boca Raton, FL: CRC Press ; 1990: 1-215.
2. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992 ; 340: 1111-1115
3. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endothelium dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990 ; 323: 22-27 (Pubitemid 20209468)
4. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension. 1993 ; 21: 929-933 (Pubitemid 23166942)
5. Rossi R, Chiurlia E, Nuzzo A, Cioni E, Origliani G, Modena MG. Flow-mediated vasodilation and the risk of developing hypertension in healthy postmenopausal women. J Am Coll Cardiol. 2004 ; 44: 1636-1640 (Pubitemid 39369796)
6. Taddei S, Salvetti A. Endothelial dysfunction in essential hypertension: clinical implications. J Hypertens. 2002 ; 20: 1671-1674
7. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, et al. Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005 ; 23: 233-246 (Pubitemid 40279622)
8. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation. 2001 ; 104: 191-196 (Pubitemid 32655837)
9. Muiesan ML, Salvetti M, Paini A, Monteduro C, Galbanini G, Poisa P, et al. Prognostic role of flow-mediated dilatation on the brachial artery in hypertensive patients. J Hypertens. 2008 ; 26: 1612-1618
10. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol. 2002 ; 40: 505-510 (Pubitemid 34833167)
11. Muiesan ML, Salvetti M, Monteduro C, Rizzoni D, Zulli R, Corbellini C, et al. Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension. Hypertension. 1999 ; 33: 575-580 (Pubitemid 29065723)
12. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs. 2002 ; 62: 265-284 (Pubitemid 34169434)
13. Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. J Hypertens. 2003 ; 41: 1281-1286 (Pubitemid 36706078)
14. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fogard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007 ; 25: 1751-1762 (Pubitemid 47356612)
15. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002 ; 39: 257-265 (Pubitemid 34084631)
16. Rossi R, Nuzzo A, Origliani G, Modena MG. Prognostic role of flow-mediated dilation and cardiac risk factors in post-menopausal women. J Am Coll Cardiol. 2008 ; 51: 997-1002 (Pubitemid 351318128)
17. Osto E, Coppolino G, Volpe M, Cosentino F. Restoring the dysfunctional endothelium. Curr Pharm Des. 2007 ; 13: 1053-1068 (Pubitemid 46696560)
18. Landmesser U, Drexler H. Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide. J Hypertens Suppl. 2006 ; 24: S39 - S43
19. Savoia C, Schiffrin EL. Inhibition of the renin angiotensin system: implications for the endothelium. Curr Diab Rep. 2006 ; 6: 274-278 (Pubitemid 44322699)
20. Neutel JM. Effect of the renin-angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function. J Hum Hypertens. 2004 ; 18: 599-606 (Pubitemid 39236424)
21. Park JB, Schiffrin EL. Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J Hypertens. 2001 ; 19: 921-930 (Pubitemid 32436957)
22. Rizzoni D, Porteri E, De Ciuceis C, et al. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus. Hypertension. 2005 ; 45: 659-665 (Pubitemid 40418362)
23. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension. 2006 ; 47: 312-318 (Pubitemid 43740260)
24. Joffe HV, Alder KA. Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev. 2005 ; 10: 31-37 (Pubitemid 40895314)
25. Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci. 2002 ; 103: 425-431 (Pubitemid 35193248)
26. Virdis A, Neves MF, Amir F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002 ; 40: 504-510
27. Freel EM, Connell JM. Mechanisms of hypertension: the expanding role of aldosterone. J Am Soc Nephrol. 2004 ; 15: 1993-2001 (Pubitemid 39031338)
28. Cachofeiro V, Miana M, de Las Heras N, Martin-Fernandez B, Ballesteros S, Fernandez-Tresguerres J, et al. Aldosterone and the vascular system. J Steroid Biochem Mol Biol. 2008 ; 109: 331-335
29. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003 ; 108: 1831-1838 (Pubitemid 37296092)
30. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive exracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insight from the randomized aldactone evaluation study (RALES). Circulation. 2000 ; 102: 2700-2706
31. Modena MG, Aveta P, Menozzi A, Rossi R. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J. 2001 ; 141: 41-46 (Pubitemid 32061310)
32. Struthers AD. Aldosterone blockade in heart failure. J Renin Angiotensin Aldosterone Syst. 2004 ; 5: S23 - S27
33. O'Keefe JH, Abuissa H, Pitt B. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. Diabetes Obes Metab. 2008 ; 10: 492-497 (Pubitemid 351639092)
34. Boccanelli A, Mureddu GF, Cacciatore G, Clemenza F, Di Lenarda A, Gavazzi A, et al. AREA IN-CHF Investigators. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. Eur J Heart Fail. 2009 ; 11: 68-76
35. Sadee W, Dagcioglu M, Schroder R. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans. J Pharmacol Exp Ther. 1973 ; 185: 686-695
36. Serafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008 ; 52: 1749-1757